Albert Markus Kasel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Albert Markus Kasel has a total of 320 co-authors. Here are the top co-authors by number of shared publications:
Adnan Kastrati
Department of Cardiology, Deutsches Herzzentrum München, Technische Universität München, DZHK (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany
23 shared publicationsHeribert Schunkert
German Heart Centre Munich, Technical University Munich, Munich, Germany
18 shared publicationsCostanza Pellegrini
German Heart Centre Munich, Technical University Munich, Munich, Germany
15 shared publicationsJonathan Michel
Univ Zurich, Univ Heart Ctr, Univ Hosp Zurich, Dept Cardiol, Zurich, Switzerland
15 shared publicationsAntonio H. Frangieh
German Heart Centre Munich, Technical University Munich, Munich, Germany
13 shared publications- Nicola Patrick Mayr
Institute of Anesthesiology, German Heart Center Munich, School of Medicine and Health, TUM University Hospital, Technical University of Munich, Munich, Germany
13 shared publications
Latest Publications
- Open Access
- 12 October 2026
- Published by Wolters Kluwer Health in Investigative Radiology
Improved Visualization of Heart Valves With 4D-CT Using a Novel Motion Correction Algorithm
Objective: Motion artifacts remain a limitation of cardiac CT when assessing both native and prosthetic heart valves, particularly during phases of rapid motion. This may lead to reduced image quality, potentially impairing the evaluation of valvular movement and pathology. The purpose of this study was to evaluate whether a novel reconstruction-based motion correction algorithm improves image quality and reduces motion artifacts of native and prosthetic heart valves compared with standard reconstructions in photon-counting detector CT (PCD-CT). Materials and Methods: In this retrospective single-center study, 57 patients [21 women; median age, 71 (interquartile range, 57 to 78 y)] who underwent clinically indicated 4D cardiac CT for suspected native and prosthetic valvular disease were included. Images were acquired using retrospectively electrocardiography (ECG)-gated spiral dual-source PCD-CT without ECG-pulsing. Images were reconstructed in 10% steps throughout the RR-interval using both standard (TrueStack) and an otherwise identical reconstruction using the novel motion correction algorithm (ZeeFreePlus). Subjective image quality and motion artifacts were independently assessed by 2 blinded, experienced readers using a 4-point visual analog scale for 3 categories: valve frame/annulus, valve leaflets, and valvular pathology. Objective analysis included quantification of the volume of artifacts throughout the cardiac cycle. Results: A total of 68 valves were evaluated, including 57 prosthetic valves (22 transcatheter aortic valve replacements and 19 surgical valves, 11 mitral valves, and 5 tricuspid valve interventions) and 11 native valves. Valvular pathology was present in 29 cases, with the most prevalent being hypoattenuated leaflet thickening in 14/29 (48%). Motion-corrected reconstructions significantly improved image quality and reduced motion artifacts across all cardiac phases and all categories (all, P P P P <0.001). Conclusions: A novel motion correction algorithm substantially reduced motion artifacts and improved image quality in both native and prosthetic heart valve imaging with PCD-CT, with the largest improvements in systole. These benefits resulted in enhanced visualization of valvular pathology, potentially reinforcing the growing clinical role of cardiac CT for the assessment of valve disease.
- 12 October 2026
- Published by Wolters Kluwer Health in Investigative Radiology
Open AccessImproved Visualization of Heart Valves With 4D-CT Using a Novel Motion Correction Algorithm
Objective: Motion artifacts remain a limitation of cardiac CT when assessing both native and prosthetic heart valves, particularly during phases of rapid motion. This may lead to reduced image quality, potentially impairing the evaluation of valvular movement and pathology. The purpose of this study was to evaluate whether a novel reconstruction-based motion correction algorithm improves image quality and reduces motion artifacts of native and prosthetic heart valves compared with standard reconstructions in photon-counting detector CT (PCD-CT). Materials and Methods: In this retrospective single-center study, 57 patients [21 women; median age, 71 (interquartile range, 57 to 78 y)] who underwent clinically indicated 4D cardiac CT for suspected native and prosthetic valvular disease were included. Images were acquired using retrospectively electrocardiography (ECG)-gated spiral dual-source PCD-CT without ECG-pulsing. Images were reconstructed in 10% steps throughout the RR-interval using both standard (TrueStack) and an otherwise identical reconstruction using the novel motion correction algorithm (ZeeFreePlus). Subjective image quality and motion artifacts were independently assessed by 2 blinded, experienced readers using a 4-point visual analog scale for 3 categories: valve frame/annulus, valve leaflets, and valvular pathology. Objective analysis included quantification of the volume of artifacts throughout the cardiac cycle. Results: A total of 68 valves were evaluated, including 57 prosthetic valves (22 transcatheter aortic valve replacements and 19 surgical valves, 11 mitral valves, and 5 tricuspid valve interventions) and 11 native valves. Valvular pathology was present in 29 cases, with the most prevalent being hypoattenuated leaflet thickening in 14/29 (48%). Motion-corrected reconstructions significantly improved image quality and reduced motion artifacts across all cardiac phases and all categories (all, P P P P <0.001). Conclusions: A novel motion correction algorithm substantially reduced motion artifacts and improved image quality in both native and prosthetic heart valve imaging with PCD-CT, with the largest improvements in systole. These benefits resulted in enhanced visualization of valvular pathology, potentially reinforcing the growing clinical role of cardiac CT for the assessment of valve disease.
- 1 October 2026
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 8 (5)
Prevalence of Left Atrial Appendage Filling Defects and Thrombus at CT for Transcatheter Aortic Valve Replacement Planning
Although left atrial appendage (LAA) filling defects are common on CT angiography for transcatheter aortic valve replacement planning, true LAA thrombus is rarely detected with late-phase imaging.
- 1 October 2026
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 8 (5)
Prevalence of Left Atrial Appendage Filling Defects and Thrombus at CT for Transcatheter Aortic Valve Replacement Planning
Although left atrial appendage (LAA) filling defects are common on CT angiography for transcatheter aortic valve replacement planning, true LAA thrombus is rarely detected with late-phase imaging.
- Open Access
- 27 May 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1710186
Partner valves: role of a prospective device selection strategy using ACURATE and SAPIEN 3 as complementary devices in transcatheter aortic valve implantation
Background: Transcatheter aortic valve implantation (TAVI) outcomes using balloon-expandable valves (BEV) and self-expanding valves (SEV) differ owing to device-specific technical features and anatomical factors. Objectives: This study aimed to evaluate prospective TAVI device selection based on anatomic features to optimise outcomes compared with published randomised data using two newer-generation devices. Methods: A total of 607 consecutive patients with severe aortic stenosis treated at a single centre from 2020 to 2023 underwent TAVI using a prospective device selection strategy. Heavy and/or asymmetric valve calcification and bicuspid anatomy were preferentially treated with SAPIEN 3/SAPIEN 3 ULTRA BEV, whereas small annulus dimensions and less calcified valves were preferentially treated with ACURATE neo/ACURATE neo2 SEV. In-hospital Valve Academic Research Consortium-3 endpoints and 1-year mortality were evaluated. Results: ACURATE was used in 182 (30%) patients and SAPIEN 3 in 425 (70%) patients. The proportion of women was higher in the ACURATE group (65% vs. 31%, p < 0.001), and patients were older (84 vs. 80 years, p < 0.001). Technical success (97% vs. 97%, p > 0.99) and new permanent pacemaker implantation during index hospitalisation (10% vs. 10%, p > 0.99) did not differ between the ACURATE and SAPIEN 3 groups. Intended performance was higher in the ACURATE group than in the SAPIEN 3 group (98% vs. 91%, p = 0.005), with aortic regurgitation ≥moderate (2% vs. p = 0.32), and mean transvalvular gradient ≥20 mmHg (p = 0.043). The estimated mortality at 1 year was 14% versus 12% (log-rank p = 0.60) in the ACURATE and SAPIEN 3 groups, respectively. Conclusions: A prospective device selection strategy using two complementary TAVI valves resulted in comparable outcomes between the SEV and BEV devices. In-hospital intended performance was higher in the ACURATE group. Despite baseline group differences, there was no difference in 1-year mortality.
- 27 May 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1710186
Open AccessPartner valves: role of a prospective device selection strategy using ACURATE and SAPIEN 3 as complementary devices in transcatheter aortic valve implantation
Background: Transcatheter aortic valve implantation (TAVI) outcomes using balloon-expandable valves (BEV) and self-expanding valves (SEV) differ owing to device-specific technical features and anatomical factors. Objectives: This study aimed to evaluate prospective TAVI device selection based on anatomic features to optimise outcomes compared with published randomised data using two newer-generation devices. Methods: A total of 607 consecutive patients with severe aortic stenosis treated at a single centre from 2020 to 2023 underwent TAVI using a prospective device selection strategy. Heavy and/or asymmetric valve calcification and bicuspid anatomy were preferentially treated with SAPIEN 3/SAPIEN 3 ULTRA BEV, whereas small annulus dimensions and less calcified valves were preferentially treated with ACURATE neo/ACURATE neo2 SEV. In-hospital Valve Academic Research Consortium-3 endpoints and 1-year mortality were evaluated. Results: ACURATE was used in 182 (30%) patients and SAPIEN 3 in 425 (70%) patients. The proportion of women was higher in the ACURATE group (65% vs. 31%, p < 0.001), and patients were older (84 vs. 80 years, p < 0.001). Technical success (97% vs. 97%, p > 0.99) and new permanent pacemaker implantation during index hospitalisation (10% vs. 10%, p > 0.99) did not differ between the ACURATE and SAPIEN 3 groups. Intended performance was higher in the ACURATE group than in the SAPIEN 3 group (98% vs. 91%, p = 0.005), with aortic regurgitation ≥moderate (2% vs. p = 0.32), and mean transvalvular gradient ≥20 mmHg (p = 0.043). The estimated mortality at 1 year was 14% versus 12% (log-rank p = 0.60) in the ACURATE and SAPIEN 3 groups, respectively. Conclusions: A prospective device selection strategy using two complementary TAVI valves resulted in comparable outcomes between the SEV and BEV devices. In-hospital intended performance was higher in the ACURATE group. Despite baseline group differences, there was no difference in 1-year mortality.
- Open Access
- 9 October 2025
- Published by Elsevier in Structural Heart
- Vol. 9 (12) , 100735
Left Atrial Appendage Occlusion Using the Amplatzer Amulet Device in High-Risk Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Intervention: A Randomized Pilot Study
- 9 October 2025
- Published by Elsevier in Structural Heart
- Vol. 9 (12) , 100735
Open AccessLeft Atrial Appendage Occlusion Using the Amplatzer Amulet Device in High-Risk Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Intervention: A Randomized Pilot Study
- Open Access
- 18 September 2025
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1678985
Editorial: Reviews in transcatheter aortic valve implantation
Transcatheter Aortic Valve Implantation (TAVI) has evolved from a last-resort therapy for inoperable or high-risk elderly patients into a well-established treatment option across all surgical risk categories. Over the past two decades, TAVI has demonstrated remarkable clinical success and is now expanding its indications to include even asymptomatic aortic stenosis. As its use extends to younger and lowerrisk populations, new challenges have emerged-ranging from lifetime management strategies such as redo-TAVI, to concerns about valve durability, anatomical complexities like bicuspid aortic valve (BAV), and the treatment of pure aortic regurgitation. In this editorial, we introduce the articles in this issue that collectively explore these evolving frontiers and outline future directions for the TAVI landscape.BAV has been considered an unfavorable anatomy for TAVI and was previously excluded from major randomized clinical trials. Key challenges associated with BAV include asymmetric and bulky calcification, large annulus and associated aortopathy (1), and heterogeneous morphologies with variable raphe types. However, with the advent of new-generation transcatheter heart valve (THVs) and advances in implantation techniques (2)(3)(4), recent studies have reported comparable outcomes in BAV compared to tricuspid aortic valve (TAV) (5). Recently, a large cohort from China showed the first evidence suggesting that the type-0 BAV may be associated with better outcomes than both TAV and type-1 BAV (6). Paravalvular regurgitation (PVR) remains the most common complication associated with BAV, with more than 40% of patients exhibiting moderate or greater degrees of PVR (7). The calcified raphe causes not only PVR but also the horizontal shift of both balloon-expandable valves (BEVs) and self-expanding valves (SEVs). In type-1 BAV, where the raphe is typically located between the left and right coronary cusps, the horizontal shift tends to displace the THVs away from the coronary ostia, potentially offering a protective effect against coronary obstruction. However, the same displacement can lead to nonanatomic valve positioning, suboptimal hemodynamics, early prosthetic valve degeneration, and increased complexity in redo-TAVI procedures. These anatomical challenges underscore the need for heightened awareness and tailored strategies to ensure durable lifetime management in BAV patients undergoing TAVI.Prior to the development of dedicated devices, several techniques using BEVs (8) and SEVs were employed to treat pure aortic regurgitation (PAR), with generally satisfactory results but a higher incidence of valve embolization. Gao et al (https://www.frontiersin.org/journals/cardiovascularmedicine/articles/10.3389/fcvm.2025.1436789/full) reported a cohort of 552 patients treated with the J-valve system (JC Medical Inc., Burlingame, CA), a transapical device featuring three U-shaped anchors positioned at the nadirs of the native cusps to ensure stable sealing. The meta-analysis demonstrated a 96% procedure success rate.Another PAR-specific device, the JenaValve, has been approved in Europe for transfemoral approach. While the use of anchoring mechanisms improves sealing, it necessitates a larger sheath for delivery, slowing the transition from transapical to transfemoral approaches. Moreover, successful deployment requires precise alignment of the three anchors at the nadirs of each cusp, demanding rotational control of the delivery system, thereby increasing procedural complexity. However, this anchoring strategy allows for surgical-like valve placement with full commissural alignment, which may enhance long-term hemodynamics and prosthetic durability (Figure 1).The rapid evolution of TAVI has been driven by relentless technological innovation.Each new generation of transcatheter valves and delivery systems has aimed to tackle the shortcomings of its predecessors -whether by reducing complication rates, expanding patient eligibility, or simplifying the procedure. Key advancements and ongoing innovations include:The latest fifth-generation Edwards SAPIEN 3 Ultra valve with RESILIA tissue exemplifies this progress, incorporating a bovine pericardial valve tissue treated with an advanced anti-calcification process (9). This proprietary RESILIA technology significantly slows calcium buildup on the leaflets -a major factor in structural valve degeneration -thereby aiming to extend valve lifespan and reduce the need for repeat interventions. In addition, the SAPIEN 3 Ultra RESILIA is the first transcatheter valve that can be stored dry (without liquid preservatives) thanks to its novel tissue preservation method, which simplifies handling and preparation during the procedure.By addressing the long-term durability challenges of earlier generations, such material innovations may broaden patient eligibility -even reaching younger, lower-risk patients who require valves with greater longevity. Moreover, new suture techniques on the commissures and the modified leaflet morphology allows significant improved hemodynamic with less gradients.Another impressive innovation of BEVs is from the Siegel transcatheter heart valve system, notable for its 8 Fr delivery profile (New York Valves 2025). This Siegel valve employs a high-strength nickel-free and cobalt-free alloy frame with only 18 cells and is delivered through an ultra-low-profile sheath, enabling treatment of patients with small-caliber vessels. Early experience indicates that the device's precise deployment (with no foreshortening) and intrinsic commissural alignment allow for accurate positioning, which is expected to reduce conduction disturbances requiring pacemaker implantation. In initial cases, the Siegel valve achieved excellent haemodynamics with low transvalvular gradients and no paravalvular leak, outcomes that were scarcely imaginable with first-generation TAVI devices. Such breakthroughs illustrate the strides being made to refine TAVI...
- 18 September 2025
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1678985
Open AccessEditorial: Reviews in transcatheter aortic valve implantation
Transcatheter Aortic Valve Implantation (TAVI) has evolved from a last-resort therapy for inoperable or high-risk elderly patients into a well-established treatment option across all surgical risk categories. Over the past two decades, TAVI has demonstrated remarkable clinical success and is now expanding its indications to include even asymptomatic aortic stenosis. As its use extends to younger and lowerrisk populations, new challenges have emerged-ranging from lifetime management strategies such as redo-TAVI, to concerns about valve durability, anatomical complexities like bicuspid aortic valve (BAV), and the treatment of pure aortic regurgitation. In this editorial, we introduce the articles in this issue that collectively explore these evolving frontiers and outline future directions for the TAVI landscape.BAV has been considered an unfavorable anatomy for TAVI and was previously excluded from major randomized clinical trials. Key challenges associated with BAV include asymmetric and bulky calcification, large annulus and associated aortopathy (1), and heterogeneous morphologies with variable raphe types. However, with the advent of new-generation transcatheter heart valve (THVs) and advances in implantation techniques (2)(3)(4), recent studies have reported comparable outcomes in BAV compared to tricuspid aortic valve (TAV) (5). Recently, a large cohort from China showed the first evidence suggesting that the type-0 BAV may be associated with better outcomes than both TAV and type-1 BAV (6). Paravalvular regurgitation (PVR) remains the most common complication associated with BAV, with more than 40% of patients exhibiting moderate or greater degrees of PVR (7). The calcified raphe causes not only PVR but also the horizontal shift of both balloon-expandable valves (BEVs) and self-expanding valves (SEVs). In type-1 BAV, where the raphe is typically located between the left and right coronary cusps, the horizontal shift tends to displace the THVs away from the coronary ostia, potentially offering a protective effect against coronary obstruction. However, the same displacement can lead to nonanatomic valve positioning, suboptimal hemodynamics, early prosthetic valve degeneration, and increased complexity in redo-TAVI procedures. These anatomical challenges underscore the need for heightened awareness and tailored strategies to ensure durable lifetime management in BAV patients undergoing TAVI.Prior to the development of dedicated devices, several techniques using BEVs (8) and SEVs were employed to treat pure aortic regurgitation (PAR), with generally satisfactory results but a higher incidence of valve embolization. Gao et al (https://www.frontiersin.org/journals/cardiovascularmedicine/articles/10.3389/fcvm.2025.1436789/full) reported a cohort of 552 patients treated with the J-valve system (JC Medical Inc., Burlingame, CA), a transapical device featuring three U-shaped anchors positioned at the nadirs of the native cusps to ensure stable sealing. The meta-analysis demonstrated a 96% procedure success rate.Another PAR-specific device, the JenaValve, has been approved in Europe for transfemoral approach. While the use of anchoring mechanisms improves sealing, it necessitates a larger sheath for delivery, slowing the transition from transapical to transfemoral approaches. Moreover, successful deployment requires precise alignment of the three anchors at the nadirs of each cusp, demanding rotational control of the delivery system, thereby increasing procedural complexity. However, this anchoring strategy allows for surgical-like valve placement with full commissural alignment, which may enhance long-term hemodynamics and prosthetic durability (Figure 1).The rapid evolution of TAVI has been driven by relentless technological innovation.Each new generation of transcatheter valves and delivery systems has aimed to tackle the shortcomings of its predecessors -whether by reducing complication rates, expanding patient eligibility, or simplifying the procedure. Key advancements and ongoing innovations include:The latest fifth-generation Edwards SAPIEN 3 Ultra valve with RESILIA tissue exemplifies this progress, incorporating a bovine pericardial valve tissue treated with an advanced anti-calcification process (9). This proprietary RESILIA technology significantly slows calcium buildup on the leaflets -a major factor in structural valve degeneration -thereby aiming to extend valve lifespan and reduce the need for repeat interventions. In addition, the SAPIEN 3 Ultra RESILIA is the first transcatheter valve that can be stored dry (without liquid preservatives) thanks to its novel tissue preservation method, which simplifies handling and preparation during the procedure.By addressing the long-term durability challenges of earlier generations, such material innovations may broaden patient eligibility -even reaching younger, lower-risk patients who require valves with greater longevity. Moreover, new suture techniques on the commissures and the modified leaflet morphology allows significant improved hemodynamic with less gradients.Another impressive innovation of BEVs is from the Siegel transcatheter heart valve system, notable for its 8 Fr delivery profile (New York Valves 2025). This Siegel valve employs a high-strength nickel-free and cobalt-free alloy frame with only 18 cells and is delivered through an ultra-low-profile sheath, enabling treatment of patients with small-caliber vessels. Early experience indicates that the device's precise deployment (with no foreshortening) and intrinsic commissural alignment allow for accurate positioning, which is expected to reduce conduction disturbances requiring pacemaker implantation. In initial cases, the Siegel valve achieved excellent haemodynamics with low transvalvular gradients and no paravalvular leak, outcomes that were scarcely imaginable with first-generation TAVI devices. Such breakthroughs illustrate the strides being made to refine TAVI...
- Open Access
- 1 March 2025
- Published by Elsevier in Structural Heart
- Vol. 9 (6)
Novel Technique Employing Transcatheter Balloon-Expandable Valves in Pure Aortic Regurgitation: A Proof-of-Concept Study
- 1 March 2025
- Published by Elsevier in Structural Heart
- Vol. 9 (6)
Open AccessNovel Technique Employing Transcatheter Balloon-Expandable Valves in Pure Aortic Regurgitation: A Proof-of-Concept Study
- Open Access
- 19 January 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (2) , 224
Relationship Between Myocardial Strain and Extracellular Volume: Exploratory Study in Patients with Severe Aortic Stenosis Undergoing Photon-Counting Detector CT
Background/Objectives: Diffuse myocardial fibrosis and altered deformation are relevant prognostic factors in aortic stenosis (AS) patients. The aim of this exploratory study was to investigate the relationship between myocardial strain, and myocardial extracellular volume (ECV) in patients with severe AS with a photon-counting detector (PCD)-CT. Methods: We retrospectively included 77 patients with severe AS undergoing PCD-CT imaging for transcatheter aortic valve replacement (TAVR) planning between January 2022 and May 2024 with a protocol including a non-contrast cardiac scan, an ECG-gated helical coronary CT angiography (CCTA), and a cardiac late enhancement scan. Myocardial strain was assessed with feature tracking from CCTA and ECV was calculated from spectral cardiac late enhancement scans. Results: Patients with cardiac amyloidosis (n = 4) exhibited significantly higher median mid-myocardial ECV (48.2% versus 25.5%, p = 0.048) but no significant differences in strain values (p > 0.05). Patients with prior myocardial infarction (n = 6) had reduced median global longitudinal strain values (−9.1% versus −21.7%, p < 0.001) but no significant differences in global mid-myocardial ECV (p > 0.05). Significant correlations were identified between the global longitudinal, circumferential, and radial strains and the CT-derived left ventricular ejection fraction (EF) (all, p < 0.001). Patients with low-flow, low-gradient AS and reduced EF exhibited lower median global longitudinal strain values compared with those with high-gradient AS (−15.2% versus −25.8%, p < 0.001). In these patients, the baso-apical mid-myocardial ECV gradient correlated with GLS values (R = 0.28, p = 0.02). Conclusions: In patients undergoing PCD-CT for TAVR planning, ECV and GLS may enable us to detect patients with cardiac amyloidosis and reduced myocardial contractility
- 19 January 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (2) , 224
Open AccessRelationship Between Myocardial Strain and Extracellular Volume: Exploratory Study in Patients with Severe Aortic Stenosis Undergoing Photon-Counting Detector CT
Background/Objectives: Diffuse myocardial fibrosis and altered deformation are relevant prognostic factors in aortic stenosis (AS) patients. The aim of this exploratory study was to investigate the relationship between myocardial strain, and myocardial extracellular volume (ECV) in patients with severe AS with a photon-counting detector (PCD)-CT. Methods: We retrospectively included 77 patients with severe AS undergoing PCD-CT imaging for transcatheter aortic valve replacement (TAVR) planning between January 2022 and May 2024 with a protocol including a non-contrast cardiac scan, an ECG-gated helical coronary CT angiography (CCTA), and a cardiac late enhancement scan. Myocardial strain was assessed with feature tracking from CCTA and ECV was calculated from spectral cardiac late enhancement scans. Results: Patients with cardiac amyloidosis (n = 4) exhibited significantly higher median mid-myocardial ECV (48.2% versus 25.5%, p = 0.048) but no significant differences in strain values (p > 0.05). Patients with prior myocardial infarction (n = 6) had reduced median global longitudinal strain values (−9.1% versus −21.7%, p < 0.001) but no significant differences in global mid-myocardial ECV (p > 0.05). Significant correlations were identified between the global longitudinal, circumferential, and radial strains and the CT-derived left ventricular ejection fraction (EF) (all, p < 0.001). Patients with low-flow, low-gradient AS and reduced EF exhibited lower median global longitudinal strain values compared with those with high-gradient AS (−15.2% versus −25.8%, p < 0.001). In these patients, the baso-apical mid-myocardial ECV gradient correlated with GLS values (R = 0.28, p = 0.02). Conclusions: In patients undergoing PCD-CT for TAVR planning, ECV and GLS may enable us to detect patients with cardiac amyloidosis and reduced myocardial contractility
- Open Access
- 8 August 2024
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 11, 1437626
Alternative access in transcatheter aortic valve replacement—an updated focused review
Aortic Stenosis (AS) is a common condition with an estimated pooled prevalence of all AS in the elderly population at around 12.4%, with that of severe AS estimated to be around 3.4%. In the past, surgical aortic valve replacement was the primary treatment option for severe AS for decades. However, with the compelling evidence on the safety and efficacy of transcatheter aortic valve replacement (TAVR), it has become the gold standard treatment option for many patients with symptomatic severe AS. Transfemoral access has been the preferred method for transcatheter heart valve delivery. However, the prevalent use of TAVR on a diverse patient profile with different risk factors, such as peripheral artery disease, precluded the possibility of a transfemoral approach despite the improvement of valves and delivery systems technology. Therefore, alternative TAVR approaches have gained increasing utility in cases where transfemoral access is unfavorable. We review the journey, evolution, and techniques for different approaches of percutaneous TAVR, including transfemoral, transcarotid, transsubclavian/transaxillary, and transcaval approaches, in addition to the traditional “surgical” transaortic and transapical accesses. Consolidating these data highlights each approach's practicality and limitations, providing additional grounding for case-by-case utilization and future clinical research.
- 8 August 2024
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 11, 1437626
Open AccessAlternative access in transcatheter aortic valve replacement—an updated focused review
Aortic Stenosis (AS) is a common condition with an estimated pooled prevalence of all AS in the elderly population at around 12.4%, with that of severe AS estimated to be around 3.4%. In the past, surgical aortic valve replacement was the primary treatment option for severe AS for decades. However, with the compelling evidence on the safety and efficacy of transcatheter aortic valve replacement (TAVR), it has become the gold standard treatment option for many patients with symptomatic severe AS. Transfemoral access has been the preferred method for transcatheter heart valve delivery. However, the prevalent use of TAVR on a diverse patient profile with different risk factors, such as peripheral artery disease, precluded the possibility of a transfemoral approach despite the improvement of valves and delivery systems technology. Therefore, alternative TAVR approaches have gained increasing utility in cases where transfemoral access is unfavorable. We review the journey, evolution, and techniques for different approaches of percutaneous TAVR, including transfemoral, transcarotid, transsubclavian/transaxillary, and transcaval approaches, in addition to the traditional “surgical” transaortic and transapical accesses. Consolidating these data highlights each approach's practicality and limitations, providing additional grounding for case-by-case utilization and future clinical research.
- Open Access
- 6 July 2024
- Published by Springer Nature in The International Journal of Cardiovascular Imaging
- Vol. 41 (1) , 177-179
Role of imaging in third aortic valve implantation: TAV-in-TAV-in-SAV
Coronary obstruction remains a primary concern for redo transcatheter aortic valve implantation (TAVI) due to supra-annular leaflets. Hereby, we present two valve-in-valve-in-valve cases, initially incorporating a surgical valve implanted to clarify our concept that the surgical valve serves to safeguard against the coronary ostium obstruction.
- 6 July 2024
- Published by Springer Nature in The International Journal of Cardiovascular Imaging
- Vol. 41 (1) , 177-179
Open AccessRole of imaging in third aortic valve implantation: TAV-in-TAV-in-SAV
Coronary obstruction remains a primary concern for redo transcatheter aortic valve implantation (TAVI) due to supra-annular leaflets. Hereby, we present two valve-in-valve-in-valve cases, initially incorporating a surgical valve implanted to clarify our concept that the surgical valve serves to safeguard against the coronary ostium obstruction.